Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ACCORD Phase 3 Trial in Alzheimer’s Disease Agitation
28 nov. 2022 06h35 HE
|
Axsome Therapeutics, Inc.
AXS-05 statistically significantly delayed time to relapse of Alzheimer’s disease agitation versus placebo (p=0.014, primary endpoint) AXS-05 statistically significantly prevented relapse of...
Attralus and Ossianix Announce an Option and License Agreement using the TXP1 Brain Shuttle for Targeted Delivery of AT-04, a Pan-Amyloid Removal Therapeutic, for Neurodegenerative Disorders
17 nov. 2022 07h00 HE
|
Attralus, Inc
SAN FRANCISCO and PHILADELPHIA, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with...
Vaccinex Reports Third Quarter 2022 Results and Provides Corporate Update
14 nov. 2022 08h30 HE
|
Vaccinex, Inc.
Promising initial responses in Phase 1b/2 open-label KEYNOTE B84 study of pepinemab with KEYTRUDA® in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patient enrollment continues in the...
Sinaptica Therapeutics Announces Publication of Positive Results from Phase II Trial Evaluating the Potential of Precision-Delivered Noninvasive Neurostimulation Treatment for Mild-to-Moderate Alzheimer’s Disease
25 oct. 2022 07h15 HE
|
Sinaptica Therapeutics
Phase II sham-controlled randomized trial met its primary endpoint with statistical significance; treatment slowed cognitive decline by 82% over 6 months in the treated population compared to sham...
Global Neurological Biomarkers Market is Expected to Reach $18.9 Billion by 2031: Says AMR
27 sept. 2022 12h00 HE
|
Allied Market Research
Portland, OR, Sept. 27, 2022 (GLOBE NEWSWIRE) -- A new business intelligence report released by Allied Market Research, the global Neurological Biomarkers Market size was estimated at $5.4 billion...
ADM Diagnostics, Inc. Awarded $1.96 Million Grant From the National Institutes of Health
27 sept. 2022 09h00 HE
|
ADM Diagnostics Inc
NORTHBROOK, Ill., Sept. 27, 2022 (GLOBE NEWSWIRE) -- ADM Diagnostics, Inc. (ADMdx) has been awarded a two-year $1.96 million Phase II Small Business Innovation Research (SBIR) grant from the...
Study of Constant Therapy Shows Promise of Sustained Cognitive Function in Alzheimer’s Disease Patients
12 sept. 2022 11h38 HE
|
Constant Therapy Health
LEXINGTON, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Constant Therapy Health, a brain health digital therapeutics company, announced today the publication of a feasibility study of its Constant...
Attralus Presents Preclinical Data Demonstrating Potent Binding to All Types of Systemic and Cerebral Amyloid by its Pan-Amyloid Removal Candidate AT-04 at 18th International Symposium on Amyloidosis
07 sept. 2022 07h00 HE
|
Attralus, Inc
AT-04 demonstrates potent binding and promotes phagocytosis in ATTR and AL amyloidosisAT-04 binds potently to Aβ, tau, and α-synuclein, common amyloid pathologies in CNS disorders such as Alzheimer's ...
Vaccinex Reports Second Quarter 2022 Results and Provides Corporate Update; Excellent Progress in Pepinemab Clinical Programs
15 août 2022 08h10 HE
|
Vaccinex, Inc.
Promising initial responses in continuing Phase 1b/2 KEYNOTE B84 study of pepinemab with KEYTRUDA® in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Phase 2 SIGNAL-HD Study Published in...
World to Witness Surging Use of Neurostimulation & Neuromodulation Devices for Nerve Repair and Regeneration, Predicts Fact.MR
04 août 2022 09h00 HE
|
FACT.MR
United States, Rockville MD, Aug. 04, 2022 (GLOBE NEWSWIRE) -- As per an in-depth industry analysis by Fact.MR, a market research and competitive intelligence provider, global demand for nerve...